Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21942211 | 0.87 | BLM (0.33) | BLMPMP22HSD17B10 | |
| SCHEMBL24864460 | 0.82 | BLM (0.62) | BLMPMP22HSD17B10 | |
| SCHEMBL1536707 | 0.81 | STING1 (0.37) | STING1 | |
| SCHEMBL5737163 | 0.81 | STING1 (0.37) | STING1 | |
| SCHEMBL5735427 | 0.81 | STING1 (0.37) | STING1 | |
| SCHEMBL29155906 | 0.81 | STING1 (0.37) | STING1 | |
| SCHEMBL18843243 | 0.81 | STING1 (0.37) | STING1 | |
| SCHEMBL25933065 | 0.81 | STING1 (0.37) | STING1 | |
| SCHEMBL18059176 | 0.81 | CA12 (0.40) | BLMPMP22HSD17B10STING1 | |
| SCHEMBL31524058 | 0.81 | CA12 (0.40) | BLMPMP22HSD17B10STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720281-A2 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | Tangram Therapeutics PLC (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085314-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | E THERAPEUTICS PLC (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4388099-B1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | TANGRAM THERAPEUTICS PLC (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4707391-A1 | NUCLEIC ACID COMPOUNDS FOR ZPI INHIBITION | e-therapeutics PLC (GB) | 2026-03-11 | — | — | EP | disclosed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| EP-4662314-A2 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | E-Therapeutics plc (GB) | 2025-12-17 | — | — | EP | disclosed |
| EP-4662315-A2 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | E-Therapeutics plc (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-20250376680-A1 | NUCLEIC ACID COMPOUNDS | E-THERAPEUTICS PLC (GB) | 2025-12-11 | — | — | US | disclosed |
| US-20250368992-A1 | NUCLEIC ACID COMPOUNDS | E THERAPEUTICS PLC (GB) | 2025-12-04 | — | — | US | disclosed |
| EP-4652283-A1 | NUCLEIC ACID COMPOUNDS FOR ZPI INHIBITION | E-Therapeutics plc (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-2587263-A1 | Self coupling recombinant antibody fusion proteins | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20110014216-A1 | Drug Transfer Based on Coenzyme A and Acyl Carrier Protein | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014196-A1 | Drug Transfer into Living Cells | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20100183516-A1 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100093553-A1 | Solid Substrate Comprising Array of Dendrons and Methods for Using the Same | PARK JOON WON | 2010-04-15 | — | — | US | disclosed |
| EP-2171456-A2 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009043899-A1 | DRUG TRANSFER INTO LIVING CELLS | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043900-A1 | DRUG TRANSFER BASED ON COENZYME A AND ACYL CARRIER PROTEIN | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009013359-A2 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | FRAUNHOFER GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2009-01-29 | — | — | WO | disclosed |
| US-20080274915-A1 | Solid Substrate Comprising Array of Dendrons and Methods for Using the Same | PARK JOON WON | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014196-A1 | Drug Transfer into Living Cells | TSPO, MPI, ABCB1 | BLM 4750/4885PMP22 3320/4885HSD17B10 2337/4885 |
| US-20250376680-A1 | NUCLEIC ACID COMPOUNDS | POLRMT, POLM, POLI | BLM 310/4885PMP22 1562/4885HSD17B10 1848/4885 |
| US-20110014216-A1 | Drug Transfer Based on Coenzyme A and Acyl Carrier Protein | COASY, ACAT2, ACAT1 | BLM 4885/4885PMP22 1598/4885HSD17B10 255/4885 |
| US-20260085314-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | NSUN2, POLRMT, MED1 | BLM 876/4885PMP22 2989/4885HSD17B10 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.